Health ❯ Healthcare ❯ Obesity

Weight Management

GLP-1 Drugs Medications Mounjaro GLP-1 Receptor Agonists Medication Management Tirzepatide Prescription Medications Hormonal Treatments Dietary Interventions Dietary Medications Semaglutide for Weight Loss Weight-loss Injections Appetite Control GLP-1 Treatment Prescription Guidelines Lifestyle Changes Belly Fat Hormonal Imbalance Anti-obesity Injections Medication Effects Weight Loss Treatments Patient Experiences Diabetes Management NHS Rollout Guidelines Fat Jabs Dietary Strategies Anti-Obesity Medications Medication Options NHS Treatments Patient Support Weight Loss Drugs Semaglutide Belly Fat Reduction GLP-1 Drugs for Obesity Deprescription Strategies Semaglutide Trials Menopause Ozempic Clinical Outcomes Therapeutic Efficacy Diet and Exercise Behavioral Interventions Incretin-based Therapies Compounded Medications Weight Loss Alternatives GLP-1/GIP Dual Agonists Drug Treatments Semaglutide Effects Weight Regain Weight Loss Programs Medication Efficacy BMI Calculations Public Health Weight Loss Medications Tirzepatide for Obesity Dietary Supplements BMI Medication Treatment Options

Lancet Analysis: Semaglutide Cuts Major Heart Events Regardless of Weight Loss

The finding strengthens the case for prescribing GLP-1 drugs based on cardiovascular risk rather than weight alone.

Kailera Therapeutics Raises $600 Million to Fund Global Phase 3 of Obesity Drug

Phase 3 Trials Show Greater Weight Loss With 7.2 mg Injection and 25 mg Oral Semaglutide

Cue-Driven Eaters Lose More Weight on GLP-1 Drugs, Japanese Study Finds

Preoperative GLP-1 Agonists Linked to Weight Loss Without Raising Postoperative Risk

Meta-Analysis Finds Predictable Weight Rebound After Stopping Anti-Obesity Drugs

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial

Novo Nordisk’s Amycretin Achieves Up to 24% Weight Loss as It Advances to Phase 3

Bariatric Surgery Surpasses GLP-1 Drugs in Real-World Weight Loss

Real-World GLP-1 Therapy Yields Lower Weight Loss, Spurs Tetra-Receptor Drug Research